Overview

Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-06-27

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of a single injection of three dose levels of ABO1105 in adults aged 18 years or above.

Phase:

PHASE1

Details

Lead Sponsor:

Suzhou Abogen Biosciences Co., Ltd.

Collaborator:

Abogen Biosciences (Shanghai) Co., Ltd